Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986142 DDI Study with CYP and P-gp Probes
NCT02762123Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986142 in rheumatoid arthritis (RA) (2 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration and 1 more. Started May 2016; status: completed.
02
Drugs
BMS-986142
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02762123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762123.